Willis Towers Watson Free cash flow decreased by 109.2% to -$65.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 24.4%, from -$86.00M to -$65.00M. Over 2 years (FY 2023 to FY 2025), Free cash flow shows an upward trend with a 18.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $275.75M | $275.75M | $275.75M | $275.75M | -$36.00M | $341.00M | $419.00M | $543.00M | -$86.00M | $303.00M | $621.00M | $708.00M | -$65.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -113.1% | >999% | +22.9% | +29.6% | -115.8% | +452.3% | +105.0% | +14.0% | -109.2% |
| YoY Change | — | — | — | — | -113.1% | +23.7% | +51.9% | +96.9% | -138.9% | -11.1% | +48.2% | +30.4% | +24.4% |